Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15 by Nelson, George W. et al.
Dense mapping of MYH9 localizes the strongest
kidney disease associations to the region of introns
13 to 15
George W. Nelson1, Barry I. Freedman2, Donald W. Bowden2, Carl D. Langefeld2, Ping An1,
Pamela J. Hicks2, Meredith A. Bostrom2, Randall C. Johnson1, Jeffrey B. Kopp3
and Cheryl A. Winkler1, 
1Laboratory of Genomic Diversity, SAIC-Frederick, Inc, NCI-Frederick, Frederick, MD, USA,
2Wake Forest University
School of Medicine, Winston-Salem, NC, USA and
3Kidney Disease Section, National Institute of Diabetes, Digestive,
and Kidney Disease, National Institutes of Health, Bethesda, MD, USA
Received September 17, 2009; Revised January 18, 2010; Accepted January 25, 2010
Admixture mapping recently identiﬁed MYH9 as a susceptibility gene for idiopathic focal segmental glomer-
ulosclerosis (FSGS), HIV-associated nephropathy (HIVAN) and end-stage kidney disease attributed to hyper-
tension (H-ESKD) in African Americans (AA). MYH9 encodes the heavy chain of non-muscle myosin IIA, a
cellular motor involved in motility. A haplotype and its tagging SNPs spanning introns 12–23 were most
strongly associated with kidney disease (OR 2–7; P < 10
28, recessive). To narrow the region of association
and identify potential causal variation, we performed a dense-mapping study using 79 MYH9 SNPs in AA
populations with FSGS, HIVAN and H-ESKD (typed for a subset of 46 SNPs), for a total of 2496 cases and con-
trols. The strongest associations were for correlated SNPs rs5750250, rs2413396 and rs5750248 in introns 13,
14 and 15, a region of 5.6 kb. Rs5750250 showed OR 5.0, 8.0 and 2.8; P 5 2 3 10
217,23 10
210 and 3 3 10
222,
respectively, for FSGS, HIVAN and H-ESKD; OR 5.7; P 5 9 3 10
227 for combined FSGS and HIVAN, recessive.
An independent association was observed for rs11912763 in intron 33. Neither the highly associated SNPs
nor the results of resequencing MYH9 in 40 HIVAN or FSGS cases and controls revealed non-synonymous
changes that could account for the disease associations. Rs2413396 and one of the highly associated
SNPs in intron 23, rs4821480, are predicted splicing motif modiﬁers. Rs5750250 combined with rs11912763
had receiver operator characteristic (ROC) C statistics of 0.80, 0.73 and 0.65 for HIVAN, FSGS and H-ESKD,
respectively, allowing prediction of genetic risk by typing two SNPs.
INTRODUCTION
Chronic kidney disease (CKD) is a major health disparity in
the USA, with the risk for end-stage kidney disease (ESKD)
4-fold higher in African Americans (AA) compared with
European Americans (EA) (1). The three leading causes of
ESKD are diabetic nephropathy, hypertensive kidney disease
and glomerulonephritis; African descent individuals are at
increased risk for all three. Using admixture mapping, we
recently identiﬁed MYH9, encoding non-muscle myosin IIA
heavy chain, as a main effect gene for idiopathic focal seg-
mental glomerulosclerosis (FSGS) and HIV-associated
nephropathy (HIVAN), which manifests as collapsing glomer-
ulopathy, and as a risk predictor for end-stage kidney disease
attributed to hypertension (H-ESKD) in the AA population (2).
The MYH9 E-1 risk haplotype has attributable risks of 70 and
100%, respectively, for sporadic FSGS and HIVAN, and
several MYH9 SNPs have odds ratios (OR) in the 4–7 range
(2). The association with MYH9 was identiﬁed independently
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pathy and Diabetes (FIND) Study (3). More recently, in a large
study of 751 type 2 diabetic ESKD (T2DM-ESKD) cases and
1152 controls, MYH9 SNPs and haplotypes were associated
with diabetic ESKD with odds ratios in the 1.2–1.4 range
(4). These studies indicate that MYH9 is a renal susceptibility
gene for the major forms of kidney disease (5). The most
strongly associated MYH9 risk alleles and risk haplotypes
are very common (frequency . 60%) in populations of
African ancestry, but rare or absent in non-African descent
individuals, providing a genetic basis for the excess risk of
CKD and ESKD in the African American population and the
familial clustering of kidney disease from disparate etiologies
observed in African American families (2,6).
A number of correlated MYH9 SNPs, including four tagging
SNPs (rs4821480, rs2032487, rs4821481 and rs3752462)
spanning introns 12–23 ( 14.9 kb), are highly associated
with FSGS and HIVAN. Although the intron 23 SNP,
rs4821481, showed the strongest, most consistent SNP associ-
ation, the African-origin E-1 haplotype (60% in AA and ,4%
EA) was more strongly associated with kidney disease and
more informative than any single SNP (2). The alternative
E2 non-risk haplotype (frequency 69% in EA and 20.5% in
AA) was strongly associated with reduced risk for FSGS and
HIVAN (OR 0.24, 0.12, 10
29 , P , 10
25, respectively) but
less so for H-ESKD (0.63, P ¼ 0.05) (2). Many of the associ-
ations, including the E-1 haplotype, were signiﬁcant for the
additive and dominant models, but the signals were most
robust for the recessive model (2). Freedman et al. (7,8) ident-
iﬁed a second region of association with H-ESKD and
T2DM-ESKD for the L-1 haplotype tagged by SNPs rs7078,
rs12107, rs735853 and rs5756129 at the 30-end of the gene.
These studies securely establish the importance of MYH9 in
kidney disease; however, they have not yet revealed causal
alleles or sequence variation.
We were motivated to ﬁne map MYH9 with additional
tagging SNPs to reﬁne the region of SNP association and loca-
lize causal sequence variation. We also sought to determine
the most informative SNPs for potential genetic screening
and personalized medicine, since the MYH9 risk alleles are
both highly frequent and have strong effects for a spectrum
of common renal diseases (2,3,7,9). The populations in this
study include subjects with biopsy-proven HIVAN with col-
lapsing glomerulopathy and biopsy-proven FSGS as these phe-
notypes show the strongest MYH9 associations and a larger
group of AA with ESKD attributed historically to hyperten-
sion (H-ESKD).
RESULTS
The region of interest for the ﬁne-mapping effort included the
entire MYH9 gene (Chr 22 coordinates 35007272 to 35113927,
106.5 kb, Build 36.3). The data set includes 17 SNPs from our
original study (2), together with 62 additional tagging SNPs
for the HIVAN and FSGS case/control groups and a subset
of 46 SNPs for the H-ESKD case/control groups (Table 1).
All SNP genotypes conformed to Hardy–Weinberg equili-
brium (HWE) in the combined FSGS-HIVAN control group,
except for rs2413396 whose typing was inaccurate, probably
due to the near proximity of the indel rs3842715. We
retyped rs2413396 in all groups using an RFLP assay, after
which this SNP conformed to HWE in the control groups.
This region of rs2413396 and rs3842715 was also resequenced
in a subset of subjects and this conﬁrmed the allele assign-
ments by the RFLP assay.
Odds ratios for MYH9 SNPS and for the E-1 haplotype in
the FSGS/HIVAN and H-ESKD groups were determined for
the recessive and additive models, as reported in earlier
studies. The results for the combined FSGS and HIVAN
groups are shown in Table 2; these groups were combined
because both shared the same disease mechanism (podocyte
injury) and have previously shown very similar associations
(2). Associations for 40 of the 79 SNPs ranged from 1.3  
10
25   P   4.4   10
227, recessive model, before correcting
for African ancestry, and were found across the gene. The
three strongest associations (5.8   10
224   P   4.4   10
227,
5.1   OR   5.8, recessive model, for combined HIVAN/
FSGS) occurred in introns 13 (rs5750250), 14 (rs2413396)
and 15 (rs5750248), as shown in Figure 1, Table 2. Supplemen-
tary Material, Table S1 shows the associations separately for
HIVAN and FSGS, recessive model. Supplementary Material,
Table S2 shows MYH9 associations for the additive model
for combined HIVAN and FSGS, which are similar in strength.
Analysis of H-ESKD cases and controls gave similar results,
with numerous associations across the gene; consistent with
earlier studies, the odds ratios were smaller, likely due to under-
lying phenotype heterogeneity (Table 3).
As the association of the MYH9 region with FSGS/HIVAN
was identiﬁed by admixture mapping, which ﬁnds regions with
pronounced added ancestry from the ancestral population
hypothesized to carry the disease factor, it is essential to estab-
lish that the disease association of the factors we report is not
simply tracking the increased African ancestry of FSGS/
HIVAN cases in this region. We tested this by correcting
the association results for estimated MYH9 chromosomal
ancestry, limiting subjects to the 410 cases and controls used
Table 1. Characteristics of kidney disease cases and controls
Phenotype Ancestry Cases Age at
diagnosis
Controls Age at
enrollment
Idiopathic FSGS AA 188
a 38+14 370
b 44+8
HIV-associated
nephropathy
AA 53
a 38+8 241
c 44+6
HypertensiveESKD AA 696
d 49+16 948
e 50+12
Total 937 1559
All cases and control were of African ancestry.
aIdiopathic focal segmental glomerulosclerosis (FSGS) cases and
HIV-associated nephropathy (collapsing glomerulopathy) cases were
diagnosed on kidney biopsy.
bControls for idiopathic FSGS were normal blood donors from the
NCI-Frederick Blood Donor Program and the NIH Clinical Center.
cHIV-associated nephropathy controls were hypernormal controls, who had
HIV infection for .8 years and had normal serum creatinine and normal urine
protein excretion.
dHypertensive ESKD cases were individuals in the southeastern USA who had
a clinical diagnosis but generally did not undergo kidney biopsy; the age of
hypertension diagnosis was 35+13 years.
eHypertensive ESKD controls were population (geographic) controls from the
southeastern US, 192 of whom had hypertension diagnosed at 44+13 years.
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SNP
(haplotype)
Physical
coordinate
b
Myh9
location
Risk
allele
c
Ref.
allele
Risk allele frequency
a Combined HIVAN/FSGS
association
Eur. Amer.
Donors
HapMap
YRI
AA
case
AA
control
OR P-value
(FET)
rs6000268 35111626 Exon 1 T C
A 0.00 0.18 0.16 0.15 0.9 (0.3–2.7) 1
rs2272827 35111514 Intron 1 G A
A 0.94 0.91 0.95 0.92 2 (1.2–3.4) 0.008
rs9610498 35107685 Intron 1 G
A A 0.44 0.98 0.96 0.87 3.3 (2–5.7) 2.8E207
d
rs5756168 35104758 Intron 1 C T
A 0.10 0.11 0.12 0.08 3.9 (0.9–18.9) 0.03
rs5750254 35104395 Intron 1 A A 0.70 0.71 0.77 0.73 1.4 (1–1.9) 0.06
rs16996724 35102720 Intron 1 A G 0.94 0.93 0.93 0.92 1.1 (0.7–1.8) 0.74
rs1883273 35099631 Intron 1 G A
A 0.31 0.59 0.69 0.55 2.2 (1.6–3.1) 9.0E207
rs6000261 35095868 Intron 1 A A 1.00 0.98 0.98 0.98 1.2 (0.5–3.4) 0.83
rs6000259 35094192 Intron 1 G
A C 1.00 0.84 0.89 0.89 1 (0.7–1.4) 0.85
rs16996701 35094078 Intron 1 G A
A 1.00 0.75 0.86 0.81 1.4 (1–1.9) 0.08
rs16996698 35091282 Intron 1 T
A C 1.00 0.99 1.00 0.99 1.6 (0.3–16) 0.73
rs136213 35089761 Intron 1 A
A G 0.31 0.45 0.60 0.44 2.5 (1.7–3.5) 3.0E207
rs136206 35085444 Intron 1 A G
A 0.27 0.66 0.74 0.59 2.2 (1.6–3) 1.2E206
rs11089788 35081047 Intron 1 C
A A 0.49 0.58 0.59 0.57 1.2 (0.8–1.6) 0.37
rs6000254 35077529 Intron 1 G
A A 1.00 0.98 1.00 0.98 8.8 (1.4–366.2) 0.008
rs6000251 35077352 Intron 1 A C
A 0.00 0.06 0.15 0.10 4.7 (1.4–18) 0.005
rs739097 35076025 Intron 1 A
A G 0.62 0.61 0.71 0.67 1.3 (0.8–2.2) 0.21
rs739096 35071686 Intron 2 G
A C 0.39 0.97 0.98 0.87 6.3 (3.3–13.2) 2.6E212
rs11913874 35067649 Intron 2 C
A G 0.98 0.83 0.89 0.87 1.3 (0.9–1.9) 0.17
rs8135022 35062938 Intron 3 T
A G 0.91 0.99 1.00 0.98 5.4 (1.3–47.4) 0.010
rs5995283 35060023 Intron 3 T
A C 1.00 0.98 1.00 0.98 4.8 (1.2–42.6) 0.02
rs6000240 35057980 Intron 3 T C 1.00 0.93 0.96 0.93 1.9 (1.1–3.6) 0.02
rs8143119 35057497 Intron 3 G
A T 0.38 0.76 0.88 0.72 3.6 (2.5–5.2) 5.6E214
rs16996677
(F-1)
35057229 Intron 3 A G
A 0.00 0.36 0.47 0.27 3.9 (2.5–6.1) 3.6E210
rs16996674
(F-1)
35056598 Intron 3 T C
A 0.00 0.33 0.43 0.24 4.1 (2.5–6.7) 4.0E209
rs5756157 35053643 Intron 3 T G
A 0.31 0.64 0.80 0.62 3 (2.2-4.2) 2.1E212
rs8136336 35052480 Intron 5 A
A G 1.00 0.94 0.98 0.97 1.7 (0.8–4.4) 0.22
rs12159211 35049109 Intron 5 G
A A 0.96 0.98 0.99 0.97 4 (1.4–15.8) 0.003
rs2071731 35048804 Intron 5 G
A A 0.67 0.78 0.83 0.75 1.7 (1.1–2.5) 0.009
rs8138583 35047578 Intron 7 T
A C 1.00 0.98 0.99 0.97 4.2 (1.3–21.5) 0.01
rs5995281 35045783 Intron 9 A G
A 0.00 0.16 0.12 0.10 1.3 (0.2–6.1) 0.72
rs1005570 35045220 Intron 10 A G
A 0.08 0.51 0.68 0.43 3.8 (2.7–5.4) 2.6E215
rs12167188 35044663 Intron 10 G A
A 0.00 0.03 0.05 0.02 Inf. 0.28
rs8141189 35044656 Intron 10 A
A T 0.00 0.36 0.44 0.27 3.8 (2.4–6.1) 3.2E209
rs2239784 35044581 Intron 10 T C
A 0.06 0.71 0.79 0.58 3.2 (2.3–4.4) 3.1E213
rs1557539 35044035 Intron 11 G
A C 1.00 0.98 0.98 0.97 2 (0.9–5.5) 0.11
rs9610489 35043477 Intron 11 C T
A 0.20 0.13 0.19 0.18 1.4 (0.6–3) 0.44
rs1557538 35042909 Intron 11 A G
A 0.29 0.67 0.77 0.64 2.2 (1.6–3) 1.1E206
rs1557536 35042756 Intron 11 C
A G 0.29 0.73 0.81 0.68 2.2 (1.6–3) 7.3E207
rs5756152 35042418 Intron 12 A G
A 0.03 0.41 0.50 0.27 4.9 (3.1–7.8) 3.2E213
rs4821484 35040465 Intron 12 C
A A 0.31 0.90 0.74 3.9 (2.7–5.8) 2.2E214
rs3752462
(E-1)
35040129 Intron 13 T C
A 0.31 0.83 0.89 0.72 3.8 (2.7–5.7) 4.0E215
rs3830104 35038570 Intron 13 T
A C 0.94 0.98 0.98 0.97 1.9 (0.8–5.2) 0.15
rs5750250
(S-1)
35038429 Intron 13 G A
A 0.04 0.68 0.82 0.52 5.7 (4–8) 9.0E227
rs2157257 35038284 Intron 13 A
A G 0.31 0.86 0.91 0.76 3.6 (2.4–5.3) 1.4E212
rs7285745
e 35038142 Exon 14 G
A A 1.00 0.98 0.99 0.97 2.5 (1–7.3) 0.04
rs2413396
(S-1)
f
35038030 Intron 14 C T
A 0.08 0.71 0.82 0.54 5.8 (4.1–8.2) 4.4E227
rs3842715 35038003 Intron 14 Ins
g Del 0.79 0.97 0.92 2.6 (1.4–5) 0.0008
rs2157256 35037607 Intron 14 A G
A 0.31 0.76 0.87 0.66 4.5 (3.1–6.4) 1.1E219
rs1557529 35035475 Intron 14 A G
A 0.03 0.54 0.60 0.36 4.1 (2.8–5.9) 5.1E214
rs2239783 35035074 Intron 15 C
A T 0.76 0.93 0.95 0.87 2.7 (1.7–4.5) 9.4E206
rs5750248
(S-1)
35032838 Intron 15 T C
A 0.04 0.70 0.83 0.56 5.1 (3.6–7.2) 5.8E224
rs1009150 35032246 Intron 16 C
A T 0.28 0.83 0.88 0.72 3.3 (2.3–4.8) 1.5E212
rs8137674 35032048 Intron 16 A G
A 1.00 0.98 0.99 0.97 3.4 (1.2–13.5) 0.01
rs17806513 35030332 Intron 18 G
A A 0.99 0.91 0.94 0.90 1.8 (1.1–2.9) 0.01
rs9619601
e 35030121 Exon 19 A G
A 0.96 0.96 0.99 0.96 3.5 (1.4–11.4) 0.004
Continued
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mate was available (Table 4); the calculated fraction of
African ancestry at MYH9 was 93% for cases and 81% for
controls, compared with the genome-wide average of 80%
for cases and 83% for controls. In this analysis, the most
strongly associated SNP, rs2413396, retained a signiﬁcance
of P ¼ 1.5   10
211, and eight SNPs retained P-values of
,10
26. Further, to test the relative contributions of
rs2413396 and local chromosomal ancestry at MYH9, we com-
pared x
2 for association of FSGS/HIVAN with MYH9 ances-
try, MYH9 SNPs, and SNPs and ancestry combined (10).
Supplementary Material, Table S3 compares these measures
for the 79 MYH9 SNPs considered; for rs2413396 for the
association of the SNP, beyond ancestry alone, showed a
P-value of 7   10
213, with P ¼ 2   10
26 for the residual
association of ancestry beyond that explained by the SNP
alone; SNP rs5750250 had similar associations. We conclude
that the majority of the strongest SNP associations is explained
by SNP rather than local ancestry association, but that a sig-
niﬁcant part of the ancestry association remains unexplained
by the SNPs. For H-ESKD, we did not have an estimate of
local chromosomal ancestry in the MYH9 region available,
as the ANCESTRYMAP program requires genome-wide
data, not available for these subjects. Hence, for these subjects,
we are limited to correcting for average chromosome 22
ancestry; with this correction, the strongest H-ESKD associ-
ated SNP, rs5750250, retained a signiﬁcance of 4   10
214,
and 13 SNPs retained P-values of ,10
26. However, as
average chromosome 22 ancestry is a poor proxy for local
MYH9 ancestry, it is less certain for H-ESKD that the
disease association of the reported SNPs is an effect indepen-
dent of local African ancestry in the MYH9 region.
AswehadpreviouslyobservedthattheE-1haplotypeassoci-
ation was stronger than any individual SNP association, we
extensively tested additional haplotypes derived from ﬁne
mapping SNPs for associations. We tested all frequent haplo-
types in HapMap haplotype blocks, and all two and three SNP
haplotypes, inferred in a moving window across all genotyped
MYH9 SNPs (11). We observed no haplotype associations
notably stronger than the individual SNP associations. The
moving window analysis did reveal a risk haplotype (AGT for
SNPs rs2157257, rs5750250 and rs3830104; OR ¼ 6.0,
P ¼ 1.2   10
227 FET for FSGS/HIVAN) and an overlapping
protective haplotype (AT for SNPs rs5750250 and rs3830104;
OR ¼ 0.17, P ¼ 1.2   10
227 for FSGS/HIVAN), complemen-
tarytotheriskhaplotype;thesehaplotypeswereinnearabsolute
Table 2. Continued
SNP
(haplotype)
Physical
coordinate
b
Myh9
location
Risk
allele
c
Ref.
allele
Risk allele frequency
a Combined HIVAN/FSGS
association
Eur. Amer.
Donors
HapMap
YRI
AA
case
AA
control
OR P-value
(FET)
rs4821481
(E-1)
35025888 Intron 23 C
A T 0.04 0.76 0.86 0.63 4.5 (3.2–6.5) 1.3E220
rs2032487
(E-1)
35025374 Intron 23 C
A T 0.04 0.76 0.86 0.64 4.2 (3–6) 1.8E218
rs4821480f
(E-1)
f
35025193 Intron 23 G
A T 0.04 0.76 0.89 0.67 4.9 (3.4–7.3) 2.2E220
rs2187776 35025119 Intron 23 C T
A 0.03 0.34 0.34 0.30 1.3 (0.7–2.1) 0.37
rs739101 35024279 Intron 24 G
A A 0.30 0.86 0.91 0.76 3.5 (2.4–5.2) 4.9E212
rs5756133 35023926 Intron 24 T
A A 0.32 0.93 0.95 0.84 3.7 (2.3–6.1) 1.7E209
rs9622373 35023618 Intron 24 C
A T 1.00 0.97 0.98 0.94 3.9 (1.7–10.1) 0.0002
rs16996648 35022698 Intron 25 C T
A 0.01 0.41 0.50 0.28 4.2 (2.7–6.6) 5.5E211
rs875725
e 35021637 Exon 26 T
A C 0.99 0.91 0.95 0.92 1.9 (1.2–3.3) 0.009
rs710181
e 35021553 Exon 26 A C
A 0.03 0.03 0.03 0.02 Inf. 0.28
rs6000233 35017908 Intron 31 C T
A 0.01 0.36 0.37 0.37 1 (0.6–1.6) 0.91
rs1476009 35016002 Intron 31 G
A A 0.97 0.96 0.96 0.96 1 (0.6–2) 1
rs11549907 35014926 Exon 33 G A 0.99 0.95 0.93 1.6 (1–2.8) 0.08
rs11912763
(F-1)
35014668 Intron 33 A G
A 0.00 0.23 0.45 0.20 7.9 (4.5–14.3) 3.3E215
rs2269529
h 35014300 Exon 34 A G 0.80 0.96 0.98 0.92 4.7 (2.2–11.4) 2.1E206
rs5756130
e 35014277 Exon 34 C T 0.98 0.87 0.94 0.88 2.1 (1.4–3.4) 0.0005
rs5756129
(L-1)
35014038 Intron 34 T C 0.78 0.83 0.91 0.80 2.8 (1.9–4.2) 4.0E208
rs2071733 35010771 Intron 38 G
A C 0.66 0.88 0.97 0.87 4.3 (2.4–8.2) 1.7E208
rs2071732 35010660 Intron 38 C
A T 0.96 0.94 0.99 0.97 3.7 (1.3–14.3) 0.007
rs735853 (L-1) 35009161 Intron 40 C G 0.52 0.97 0.99 0.88 12.4 (5.1–39.5) 1.1E214
rs735854 35009004 Intron 40 T C 0.33 0.93 0.94 0.79 4.9 (3.1–7.9) 1.3E215
rs12107 (L-1) 35007928 Exon 41
30-UTR
G
A A 0.85 0.95 0.96 0.90 3.2 (1.8–5.8) 3.7E206
rs7078 (L-1) 35007860 Exon 41
30-UTR
T
A C 0.73 0.93 0.85 2.5 (1.6–4) 5.2E206
aAllele frequencies from 221 European American normal blood donors and from the HapMap Yoruba from Nigeria (YRI) (10);
bGenome Build 36.3;
csuperscript
A indicates ancestral allele as indicated in NCBI dbSNP;
dbold indicates P , 0.001;
eSynonymous change;
fSplice motif change (predicted);
g-/TCCTGTGA;
h1626 Ile . Val.
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moresigniﬁcant.Wealsotested,inthecombinedHIVAN/FSGS
group, haplotypes with associations reported in other studies of
ESKD:L-1,andtheF-1andS-1haplotypesreportedinthecom-
panion publication (12) (Table 5). The S-1 and F-1 haplotypes
are marginally more strongly associated than the strongest con-
stituent SNPs, while the association for the L-1 haplotype was
substantially stronger (P ¼ 1.1   10
218 for L-1 versus 1.1  
10
214 for rs735853).
With regard to H-ESKD, an effect independent of the strong
association for the E-1 haplotype was previously observed for
the L-1 haplotype, carrying SNPs close to the 30-end of MYH9
(7). We tested in FSGS/HIVAN for an independent effect of
SNPs in the 30-region, and across MYH9, by running a logistic
regression with each MYH9 SNP considered as a covariate
along with rs2413396 and estimated MYH9 chromosomal
ancestry (Table 4). In this analysis, rs875725 in intron 33
had the strongest independent effect (P ¼ 6.4   10
205), with
three other SNPs in the 30-region having moderately signiﬁ-
cant (P , 0.005) associations. The three intron 23 SNPs ident-
iﬁed as the strongest factors in the earlier reports showed no
signiﬁcance in this analysis (P , 0.1) (2,3,7). Testing for
SNPs independent of MYH9 ancestry, rs2413396 and
rs875725, revealed no highly signiﬁcant effects (P . 0.03).
For the four haplotypes (E-1, S-1, L-1 and F-1), we tested
separately for effects independent of E-1 and S-1; S-1, L-1
and F-1 showed strong effects independent of E-1. E-1
showed no effect independent of S-1, while F-1 showed a
strong, and L-1 a modest independent effect. As we were inter-
ested in identifying SNPs useful for genetic testing for propen-
sity to kidney disease in AA and similar populations, for
which we sought the strongest empirical association of SNPs
with disease, independent of the mechanism of the association,
we also performed logistic regressions with each MYH9 SNP
considered as a covariate along with rs2413396 and estimated
chromosome 22 ancestry, for both FSGS/HIVAN and
H-ESKD (Tables 3 and 4). Here SNP rs11912763 was the
most strongly associated, P ¼ 7   10
25 for FSGS/HIVAN.
The high odds ratios for the strongest susceptibility factors,
for each of the kidney diseases studied, combined with the
factors’highfrequencies,makethesegeneticfactorsstrongpre-
dictorsofkidneydiseasesusceptibility.Figure2showstheROC
C statistics for haplotype E-1, rs2413396, rs5750250, and com-
binedgenotypes ofrs5750250andrs11912763,forthe HIVAN,
FSGS and H-ESKD. Rs2413396 and rs5750250 are equivalent,
and rs5750250 would be preferred for genetic testing due to the
genotyping difﬁculties ofrs2413396.Thestrongesttestusesthe
combined genotype of rs5750250 and the independent
rs11912763; this test has ROC C statistics of 0.80, 0.73 and
0.65 for HIVAN, FSGS and H-ESKD, respectively.
Figure 1. Map of MYH9 showing location of exons, and of 80 SNPs, with the strength of association of the SNP (recessive model for the risk allele) with
combined FSGS and HIVAN indicated by color. HapMap linkage disequilibrium (D0) for MYH9 is shown.
Human Molecular Genetics, 2010, Vol. 19, No. 9 1809We tested all typed MYH9 SNPs between exons 2 and 41,
inclusive, along with additional HapMap SNPs in this region
for possible effect on splicing with the splice motif prediction
program SplicePort (11,13). Cases where motif alteration by a
SNP changes predicted splice strengths that would change the
likelihood of alternative splicing (substitution of a non-
standard donor or acceptor for the standard donor or acceptor,
Supplementary Material, Fig. S2) are of interest. Two possible
splice changes are of particular interest are associated with
notable MYH9 SNPs. First, for the boundary between exon
14 and intron 14, there is an alternate donor site whose use
would reduce the size of exon 14 by 93 bp. The risk allele
of the most strongly associated variant, rs2413396, decreased
the score gap between the common splice site and the alternate
by 25%; possibly this decrease could enhance alternative spli-
cing. Although the SPLICEPORT program predicts this to be a
weak change, it deserves attention considering the strength of
the association of rs2413396. A variation predicted to have a
stronger effect on splicing occurs at the boundary between
intron 23 and exon 24, associated with rs4821480. An alter-
nate acceptor site has nearly equal strength to that for the
site used (0.43 versus 0.44) for the protective allele (T), but
for the susceptible allele (G), the alternate site motif has
much lower score 0.22. Based on these splice predictions, it
Table 3. SNP association with H-ESKD for African American cases (n ¼ 696) and controls (948), recessive model
SNP Allele frequency Unadjusted
a Adjusted for Chr 22 ancestry
b Adjusted for Chr 22 ancestry and rs2413396
c
H-ESKD Controls OR P (FET) Padj Padj
rs5995283 0.99 0.98 1.83 0.07 0.049 0.24
rs6000240 0.96 0.94 1.69 0.003 0.004 0.013
rs16996677 (F-1) 0.37 0.27 2.33 6.3E207 1.6E206 0.013
rs16996674 (F-1) 0.35 0.23 2.77 2.4E208 8.3E209 0.0028
rs5756157 0.73 0.62 2.01 2.0E211 8.1E208 0.003
rs8136336 0.98 0.97 1.49 0.11 0.11 0.06
rs12159211 0.98 0.97 1.46 0.17 0.22 0.90
rs8138583 0.98 0.98 1.45 0.19 0.12 0.67
rs5995281 0.12 0.09 2.89 0.03 0.06 0.08
rs1005570 0.56 0.44 2.17 6.9E211 2.2E207 0.005
rs8141189 0.37 0.27 2.54 1.4E207 5.6E206 0.0011
rs2239784 0.69 0.55 2.19 1.4E213 3.0E209 0.012
rs1557539 0.98 0.98 1.04 1 0.78 0.88
rs9610489 0.19 0.20 0.77 0.37 0.89 0.32
rs1557538 0.70 0.64 1.40 0.001 0.007 0.64
rs1557536 0.73 0.68 1.40 0.001 0.031 0.80
rs5756152 0.39 0.25 3.11 1.7E211 4.8E213 1.53E204
rs3752462 (E-1) 0.82 0.73 1.72 2.9E207 4.1E205 0.51
rs3830104 0.98 0.96 1.94 0.004 0.02 0.011
rs5750250 (S-1) 0.68 0.50 2.76 2.8E221 4.0E214 1.92E205
rs7285745 0.98 0.97 1.48 0.10 0.08 0.64
rs2413396 (S-1) 0.68 0.53 2.41 9.6E217 4.5E211
rs1557529 0.49 0.34 2.54 2.1E212 5.0E211 0.0029
rs2239783 0.91 0.87 1.68 6.4E205 0.0050 0.79
rs8137674 0.98 0.97 1.17 0.56 0.41 0.54
rs9619601 0.97 0.95 1.77 0.004 0.009 0.020
rs4821481 (E-1) 0.75 0.60 2.57 6.1E220 5.6E211 0.0003
rs2032487 (E-1) 0.76 0.61 2.54 3.9E219 1.9E210 0.0004
rs4821480 (E-1) 0.75 0.60 2.60 3.1E220 3.2E211 0.0001
rs2187776 0.32 0.29 1.11 0.52 0.91 0.021
rs5756133 0.91 0.85 1.93 1.8E207 8.8E204 0.31
rs9622373 0.96 0.95 1.32 0.14 0.09 0.92
rs16996648 0.40 0.26 3.79 5.2E216 7.5E213 7.59E207
rs875725 0.94 0.93 1.24 0.19 0.26 0.07
rs6000233 0.36 0.34 1.10 0.55 0.62 0.013
rs1476009 0.98 0.97 1.81 0.01 0.01 0.027
rs11549907 0.95 0.94 1.36 0.09 0.13 0.018
rs11912763 (F-1) 0.34 0.19 5.65 5.1E218 9.5E216 2.62E208
rs5756130 0.90 0.87 1.46 0.003 0.009 0.88
rs5756129g (L-1) 0.85 0.78 1.76 3.0E207 5.7E205 0.60
rs2071733 0.93 0.87 2.15 1.2E208 3.3E205 0.0018
rs2071732 0.98 0.96 2.17 0.001 0.004 0.005
rs735853g (L-1) 0.93 0.89 1.74 0.0001 0.0104 0.60
rs735854 0.87 0.79 1.85 6.3E208 1.1E204 0.050
rs12107g (L-1) 0.93 0.88 1.82 9.2E206 1.2E204 0.021
rs7078g (L-1) 0.90 0.84 1.59 9.8E205 0.001 0.45
aSigniﬁcant associations P   0.001 are in bold;
blogistic regression result adjusted for chr 22 ancestry;
clogistic regression result adjusted for chr 22 ancestry and
conditioned on rs2413396.
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tective genotype that is abrogated with the susceptible geno-
type; notably the variant splicing, although in frame,
introduces two stop codons and would likely act as a knockout
mutation. We are actively investigating the expression of alter-
nate splicing in these regions. Although the suggested splice
changes have not been previously reported, the apparently
kidney limited phenotype of MYH9 variation associated with
FSGS, HIVAN and H-ESKD suggests that alternate splicing
or alterations in expression may be speciﬁc to podocytes or
other kidney cells.
DISCUSSION
In this report, we observed very strong new associations for
MYH9 SNPs with idiopathic FSGS, HIVAN and H-ESKD,
which underscore the profound effect of variation in this
gene on major forms of kidney disease reported previously.
The strongest SNP associations are for three SNPs in introns
13, 14 and 15 (P ¼ 4   10
227 for rs2413396 in intron 14 for
combined FSGS, P ¼ 3   10
222 for rs5750250 in intron 13
for H-ESKD). The multiple associations of SNPs spanning
MYH9 are largely due to extensive linkage disequilibrium
within and between haplotype blocks; however, this study
and others suggest that multiple SNPs within the MYH9
gene predict renal disease (7), (12). We found that independent
associations remain, after conditioning on rs2413396 or
rs5750250 and controlling for ancestry for SNPs, in introns
1, 12, 33 and exon 40 (encoding the 30-UTR). An independent
association of rs11912763 in intron 33, in the region pre-
viously reported in Freedman et al. (7), is notably robust. A
companion publication in this volume (12) describes generally
similar, and correspondingly highly signiﬁcant, associations
for MYH9 SNPs and haplotypes with hypertensive ESKD in
a New York-based Hispanic cohort.
Speciﬁc MYH9 non-synonymous mutations have been
associated with giant platelet syndromes, including the spec-
trum of May-Hegglin, Epstein, Fechtner and Sebastian syn-
dromes, which include thrombocytopenia and frequently
sensori-neural deafness and/or glomerulonephritis (14). The
functional variation in MYH9 responsible for the kidney dis-
eases studied here remains elusive. Two resequencing efforts
(data not shown) detected only sporadic coding sequence vari-
ation among the set of cases and controls chosen for study,
identifying no variation frequent enough to be responsible
for the observed effects. Thus, the functional variation is evi-
dently not an amino acid substitution. The fact that the stron-
gest associations are deep inside the gene—the SNPs
rs2413396 and rs5750250 are more than 75 Kb from the
start of transcription, and separated from it by a recombination
hotspot (Fig. 1 and HapMap data) (11)—argues against a pro-
moter variant being responsible. The 30-end of MYH9 is less
distant (30 Kb), and strong independent effects are seen
close to the 30-end, thus a 30 regulatory effect is possible
(15). The presence of associations independent of the strongest
SNPs and haplotype (S-1) both closer to the 30-end of MYH9
and spanning S-1 (haplotype F-1) complicates the interpret-
ation of the association. These independent associations
could indicate either multiple functional polymorphisms, or
a complex pattern of medium-range LD reﬂecting differing
patterns of recombination in ancestral populations carrying
the risk variant, or both.
Considering the positional data, a splicing change seems a
plausible functional variation. The SNP rs2413396, the stron-
gest recessive association for FSGS, and rs4821480, in the
strongest region of association in the earlier report, intron
23, are predicted to modify splice-determining motifs. The
Table 4. Comparison of unadjusted and adjusted associations for 43 MYH9
SNPs (signiﬁcant unadjusted or adjusted) with biopsy-conﬁrmed HIVAN and
FSGS, recessive genetic model
SNP (haplotype) FETunadj Adjusted
for MYH9
ancestry
a,
P-value
Adjusted for
MYH9
ancestry and
rs2413396
b,
P-value
Adjusted for
Chr 22
ancestry and
rs2413396
c,
P-value
rs9610498 2.8E207
d 0.14 0.54 0.33
rs1883273 9.0E207 0.01 0.12 0.0009
rs136213 3.0E207 0.0008 0.02 0.01
rs136206 1.2E206 0.006 0.17 0.38
rs739096 2.6E212 0.006 0.11 0.03
rs8143119 5.6E214 8.5E207 0.01 0.04
rs16996677 (F-1) 3.6E210 0.01 0.23 0.007
rs16996674 (F-1) 4.0E209 0.03 0.74 0.05
rs5756157 2.1E212 9.3E206 0.04 0.18
rs1005570 2.6E215 6.0E205 0.09 0.02
rs8141189 3.2E209 0.001 0.04 0.004
rs2239784 3.1E213 0.002 0.66 0.58
rs1557538 1.1E206 0.03 0.60 0.23
rs1557536 7.3E207 0.09 0.94 0.12
rs5756152 3.2E213 0.007 0.31 0.0006
rs4821484 2.2E214 1.4E205 0.99 0.17
rs3752462 (E-1) 4.0E215 5.0E206 0.91 0.16
rs5750250 (S-1) 9.0E227 8.2E211 0.75 0.85
rs2157257 1.4E212 0.0002 0.74 0.48
rs2413396 (S-1) 4.4E227 1.5E211 ––
rs3842715 0.0008 0.40 0.19 0.78
rs2157256 1.1E219 1.2E209 0.17 0.02
rs1557529 5.1E214 0.0002 0.28 0.14
rs2239783 9.4E206 0.06 0.22 0.15
rs5750248 (S-1) 5.8E224 2.5E209 0.87 0.42
rs1009150 1.5E212 0.0003 0.11 0.20
rs4821481 (E-1) 1.3E220 3.8E208 0.46 0.78
rs2032487 (E-1) 1.8E218 4.2E207 0.69 0.91
rs4821480
d (E-1) 2.2E220 1.8E207 0.10 0.35
rs739101 4.9E212 0.001 0.65 0.43
rs5756133 1.7E209 0.02 0.95 0.25
rs9622373 0.0002 0.002 0.13 0.32
rs16996648 5.5E211 0.001 0.12 0.01
rs875725 0.009 0.0006 6.4E205 0.007
rs11912763 (F-1) 3.3E215 0.0002 0.02 7.5E205
rs2269529 2.1E206 0.03 0.25 0.02
rs5756130 0.0005 0.003 0.63 0.55
rs5756129 (L-1) 4.0E208 0.0004 0.89 0.73
rs2071733 1.7E208 0.01 0.05 0.009
rs735853 (L-1) 1.1E214 0.01 0.13 0.009
rs735854 1.3E215 0.0001 0.0002 0.0006
rs12107 (L-1) 3.7E206 0.08 0.59 0.04
rs7078 (L-1) 5.2E206 0.04 0.83 0.08
aAnalysis on a subset of 412 FSGS cases (190) and controls (212), corrected for
MYH9 chromosomal ancestry;
bsubset of 412 FSGS cases (190) and controls
adjusted for MYH9 ancestry and rs2413396;
cadjusted for Chr 22 ancestry and
rs2413396.
dBold indicates P , 0.001.
Human Molecular Genetics, 2010, Vol. 19, No. 9 1811risk variant for rs2413396 decreases the predicted strength
difference between the known splice site and a possible
alternative by 20%; although this is a small predicted effect,
it is of interest given the strength of association for this
SNP. A much stronger effect is predicted for the intron 23
SNP rs4821480; with the protective alleles of rs4821480, an
alternate donor site has equal predicted strength as the stan-
dard site for the start of exon 24, whereas with the risk
allele the alternate motif is substantially weaker. Thus, the
risk allele could plausibly abrogate alternate splicing.
Although the possible splice variation is in frame, it contains
two stop codons, indicating that it would have a knockout
effect, eliminating the last 20 exons. This possible splice
change cannot be the single primary functional effect, as
rs4821480 is not signiﬁcant when conditioned on re2413396,
but it could contribute to a more complex pattern of splice
and possibly expression variation.
Non-muscle myosin II molecular complexes, present in
essentially every cell, are cellular motors that contribute to
motility, adhesion, intra-cellular trafﬁcking and cytokinesis.
The variable presence of glomerulonephritis in the autosomal
dominant giant platelet syndromes suggests the important role
for these molecules in glomerular function. The glomerular
podocyte expresses non-muscle myosin IIA and B in vivo
(16) and in vitro (Kopp, unpublished data). Podocytes serve
several essential functions: they elaborate matrix proteins of
the glomerular basement membrane and their terminal foot
processes, with the interdigitating slit diaphragms, determine
the stringent permselectivity characteristics of glomerular ﬁl-
tration. Idiopathic FSGS has not been associated with extra-
renal manifestations, and while HIVAN is due to systemic
disease, there are no extra-renal manifestations that are associ-
ated speciﬁcally with these kidney diseases. H-ESKD is also
likely a primary kidney disease in spectrum of FSGS (focal
global glomerulosclerosis), without extrarenal manifestations
except for secondarily elevated blood pressures. These obser-
vations lead us to seek mechanisms by which the MYH9 vari-
ation reported here could exclusively or primarily affect the
kidney. One possibility is that MYH9 expression in podocytes
is characterized by unique mRNA splicing patterns, which
might be affected by the SNPs described here. To date, we
have no evidence supporting this hypothesis. An alternative
hypothesis is that the special structure and function of podo-
cytes places particular functional demands on the myosin–
actin cytoskeleton in maintaining the podocyte foot processes,
so that minor changes in MYH9 protein structure, or MYH9
expression affecting the relative frequency of the different
myosin heavy chain proteins, become critical.
Although we have not determined the cause of the profound
MYH9 effect on kidney disease, the identiﬁcation of more
highly associated SNPs enhances the prospects of simple,
highly informative genetic testing. This predictive power
may be measured by the ROC C statistic, which gives a
joint measure of the sensitivity and speciﬁcity of a predictive
model. The C statistics for rs5750250 genotypes (rs2413396
has equivalent predictive power but is more difﬁcult to geno-
type) was 0.76 and 0.71 for HIVAN and FSGS, respectively;
the C statistic was lower (0.61) for H-ESKD, probably due
Table 5. Haplotype associations with combined HIVAN and FSGS
Haplotype associations Strongest SNP in haplotype Haplotype associations
independent of E-1
a
Haplotype associations
independent of S-1
a
Dominant Recessive Dominant Recessive Dominant Recessive
Haplotype
b OR P (FET) OR P (FET) OR
c P (FET) OR P-value OR P-value OR P-value OR P-value
E-1 4.7 8.7E206 5.0 4.9E223 rs4821481 4.5 (rec) 1.3E220 – – – – 1.2 0.81 1.3 0.48
S-1 7.5 5.9E210 6.0 9.7E228 rs2413396 5.8 (rec) 4.4E227 2.7 0.09 3.9 0.0001 – – – –
F-1 3.8 3.1E217 6.9 1.3E210 rs11912763 3.8 (dom) 8.4E217 2.2 2.4E205 2.2 0.03 2.0 0.0005 2.2 0.04
L-1 8.2 3.2E205 4.6 1.1E218 rs735853 12.4 (rec) 1.1E214 2.8 0.20 2.4 0.0001 1.6 0.59 1.9 0.01
aHaplotypes considered as dominant and recessive variables together with dominant and recessive variables for E-1 or S-1, in logistic regression.
bSNP alleles deﬁning the haplotypes: E-1: rs4821480 G, rs2032487 C, rs4821481 C, rs3752462 T. S-1: rs5750248 T, rs2413396 C, rs5750250 G. F-1: rs11912763
A, rs16996674 T, rs16996677 A. L-1: rs7078 A, rs12107 G, rs735853 C, rs5756129 T.
cOR and P-value for the model indicated for the OR.
Figure 2. Receiver operating characteristic C statistics of haplotype E-1, SNPs
rs2413396 and rs5750250, and combined genotypes of rs5750250 and
rs11912763 as predictors of HIVAN, FSGS and H-ESKD. Statistics were cal-
culated by counting the frequency with which, in random draws of cases and
controls, the case has a more susceptible genotype than the control. For the E-1
and the SNPs, susceptibility of the genotype was taken to be the number of
copies of the risk allele. For combined rs5750250 and rs11912763, suscepti-
bility of the genotype was taken from the following ordering, from least to
most susceptible, for rs5750250/rs11912763 genotypes: AA/GG or AA/AG;
AG/GG or AG/AG; GG/GG; GG/AG; AG/AA or GG/AA.
1812 Human Molecular Genetics, 2010, Vol. 19, No. 9to phenotype variation in patients with this clinical diagnosis.
Increased predictive power is gained by considering combined
genotypes of rs5750250 and rs11912763, which give ROC C
statistics of 0.80, 0.73 and 0.65 for HIVAN, FSGS and
H-ESKD, respectively. These results would make testing
these two SNPs one of the strongest tests for genetic suscepti-
bility to a common disease. In particular, we suggest that it is
worth investigating whether, in individuals with HIV disease
who have susceptible combined genotypes of rs5750250 and
rs11912763, initiation of anti-retroviral therapy prior to the
onset of kidney disease or with the appearance of microalbu-
minuria might reduce the burden of kidney disease among
African descent individuals.
MATERIALS AND METHODS
Study participants
We studied three case groups, all self-identiﬁed as of African
descent and for simplicity described as AA (Table 1). Cases
included individuals with biopsy-proven idiopathic FSGS,
biopsy-proven HIVAN with collapsing glomerulopathy; and
H-ESKD, generally without kidney biopsy. These groups
have been previously described (2,7). Idiopathic FSGS and
HIVAN cases were enrolled from 22 academic medical
centers in the USA as part of the NIH FSGS Genetic Study.
Idiopathic FSGS cases were diagnosed according to standard
pathologic criteria; cases consistent with post-adaptive FSGS
(e.g. associated with obesity, reﬂux nephropathy and sickle
cell nephropathy) and with FSGS due to hypertension, medi-
cations or other genetic causes were excluded. HIVAN cases
had kidney biopsies that were consistent with collapsing glo-
merulopathy (also termed the collapsing variant of FSGS)
with capillary collapse and podocyte hyperplasia. H-ESKD
cases were recruited at the Wake Forest University School
of Medicine from North Carolina and neighboring states;
cases were deﬁned by hypertension prior to kidney failure
with hypertensive target organ damage and low-level protei-
nuria, when these data were available ( 30 mg/100 ml on
urine dipstick, ,0.5 g/day protein, or urine protein/creatinine
ratio ,0.5 g/g). H-ESKD cases did not have diabetes, HIV
infection or other known speciﬁc etiologies of kidney disease.
Also included were three control groups, all self-identiﬁed
as of African descent and for simplicity referred to as AA.
Controls for the FSGS cases were normal control blood
donors lacking a history of kidney disease, recruited at the
NIH Clinical Center in Bethesda, MD, and age 44+8 years
at enrollment. Controls for HIVAN were enrolled in the
AIDS Link to the Intravenous Drug Experience (ALIVE)
cohort from Baltimore, MD and HIV-infected for 8 or more
years with normal serum creatinine ( 1.4 mg/dl) and lack of
proteinuria (urine protein to creatinine ratio , 0.5); this
group represents a hypernormal control. Wake Forest controls
were recruited from the same geographic region as the
H-ESKD cases and denied a personal history of kidney
disease and denied a ﬁrst-degree relative with kidney disease
on dialysis or with a kidney allograft, as previously described
(7). The average African ancestry for the FSGS/HIVAN study,
determined on the representative subset for which genome
wide data were available, was 80% for cases and 83% for
controls; average African ancestry was 88% for cases and
86% for controls for the ESKD study. There was no overlap
of subjects (either H-ESKD cases or controls) between this
study and the study described in the companion publication;
however, the phenotype deﬁnition for H-ESKD between the
two studies was nearly identical (12).
Institutional Review Boards at each collaborating medical
center approved study protocols and each subject provided
written informed consent.
SNP selection and genotyping
The Tagger function in Haploview was used to select 61 SNPs
to extend the existing 17 typed SNPs to create a complete
tagging set for all SNPs included in the HapMap panel,
using YRI data (Table 2, Fig. 1) (11). We chose a tagging
panel to capture all HapMap SNPs across MYH9 and with
an R
2 of at least 0.95, and with an R
2 of at least 0.99 for the
region spanning intron 12–23, previously shown to be most
strongly associated with kidney disease (17). Indel
rs3842715 in intron 14 was subsequently added to the SNP
panel to resolve associations with rs2413396 as noted below.
The H-ESKD cases and Wake Forest controls were genotyped
for 46 SNPs (Table 3), a subset of the SNPs typed on the
HIVAN and FSGS cases and controls (Table 2). We corrected
for local ancestry for HIVAN, FSGS and H-ESKD using 35
diallelic ancestry informative markers (AIMs) (mean delta
difference between CEU and YRI 49.6%, range 22–76%)
across chromosome 22. For H-ESKD, 70 diallelic ancestry
informative markers (AIMS) were used to correct for genome-
wide continental ancestry as previously described (7).
MYH9 SNP genotyping was performed by TaqMan (ABI,
Foster City, CA, USA) for the idiopathic FSGS and HIVAN
cases. MYH9 SNP genotyping for the H-ESKD participants,
and AIMs genotyping for all participants, was performed on
a Sequenom Mass Array Genotyping System (Sequenom,
San Diego, CA, USA). Each SNP was tested for departures
from HWE expectations via a chi-square goodness of ﬁt test.
Deviations from HWE were observed for SNP rs2413396 in
both TaqMan and Sequenom typing, due to faulty genotyping
apparently caused by the close proximity of indel rs3842715;
therefore, rs2413396 was re-genotyped by a restriction frag-
ment length polymorphism (RFLP) assay for all subjects.
The indel rs3842715 was also genotyped by RFLP for the
FSGS and HIVAN cases and controls and added to the SNP
panel. The allele calling for these two SNPs was conﬁrmed
by sequencing.
Statistical analyses
The association between each SNP and FSGS, HIVAN, and
H-ESKD, and combined FSGS and HIVAN, was computed
for recessive and additive models by Fisher’s exact test,
using the ﬁsher.test function in R (R Foundation, www.
r-project.org). Logistic regression (function glm in R) was
used to test for association, adjusting for ancestry,
rs2413396 and rs11912763 (for HIVAN/FSGS) or for ancestry
and rs5750250 (for H-ESKD). We did not correct for multiple
comparisons, as our purpose was to reﬁne well-established
associations. However, most of the associations would
Human Molecular Genetics, 2010, Vol. 19, No. 9 1813remain signiﬁcant with the simple Bonferroni adjustment for
79 SNPs (P-value ¼ 0.0006) tested and many would remain
at a highly conservative genome-wide threshold of 1.0  
10
28.
The receiver operating characteristic (ROC) C statistic was
estimated by counting the frequency with which a case subject
carried a more risk-associated genotype than a control subject
in 1 000 000 random samplings of case and controls (18). Gen-
otypes in this analysis were grouped so each step of increased
risk was statistically signiﬁcant.
Correction for ancestry
Since African inherited alleles will generally be more common
among cases for the kidney disease studied, analyses were run
corrected for this confounding effect by including ancestry
estimates as covariates, along with the MYH9 SNP and haplo-
type effects, in logistic regression. Estimates of chromosome
22 admixture proportions were calculated for FSGS/HIVAN
with EIGENSTRAT (using the ﬁrst principal component)
using 34 AIMS on chromosome 22, and for H-ESKD with
ADMIXMAP using 35 AIMs (19–21). In addition, we
tested the subset of FSGS/HIVAN subjects included in the
admixture mapping analysis in the Kopp et al., study adjusting
for the admixture proportion determined for MYH9 by
ANCESTRYMAP, using probability estimates for carrying
one or two African chromosomes in MYH9 as separate con-
founding factors to capture both dominant and recessive
effects of ancestry (2,22). ANCESTRYMAP estimates of the
probability of an individual carrying two African chromo-
somes were also used for a test of association limited to
these individuals. As ANCESTRYMAP estimates of ancestry
at each MYH9 SNP were strongly consistent, indicating no
detected recombination in MYH9 between African and
European chromosomes, we used the average across SNPs
of the probability estimates for carrying one or two African
chromosomes.
Haplotype inference
We inferred haplotypes within local haplotype blocks deﬁned
by the conﬁdence interval method, and within longer regions
of linkage disequilibrium bounded by deﬁned recombination
hot spots, and in addition inferred the deﬁned haplotypes
E-1, S-1, L-1 and F-1, some of which extend beyond deﬁned
blocks (15,23). Haplotypes were inferred by an in-house
implementation of the expectation-maximization (EM)
algorithm (24).
Splice-site prediction
Three representative haplotypes carrying alternate MYH9
alleles were generated by inserting the alleles in genomic
sequence extending from exon 2 to exon 41, inclusive; the
haplotypes were the most common YRI haplotypes consistent
with protective (two haplotypes) and susceptible (one haplo-
type) MYH9 haplotypes from our analysis (see Supplementary
Material, Figs S1 and S2). We compared splice site predictions
from SplicePort (spliceport.cs.umd.edu/) for the three
haplotypes, looking for allele-dependent variation in predicted
splice motif strength (13).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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